Vaccines to prevent infection with the human papillomavirus (HPV) have recently been approved for use in preventing cervical precancer and cancer. This paper reviews the HPV vaccine effectiveness and cost-effectiveness studies published to date. In order to fully appreciate the strengths and limitations of the different studies, a short background is provided on the natural history of HPV and cervical cancer, current prevention strategies and HPV vaccine trial results to date. Each study is then summarized in terms of model structure, parameter estimates for the natural history of HPV and cervical cancer, assumptions regarding screening and vaccination, and key findings. The review concludes with recommendations for additional research and a five-year perspective.
|Original language||English (US)|
|Number of pages||17|
|Journal||Expert Review of Pharmacoeconomics and Outcomes Research|
|State||Published - Jun 2007|
Bibliographical noteFunding Information:
Shalini Kulasingam is currently supported by an NIH career development award (NIH 1K07 CA113773). She has previously received grants and/or been a consultant for Merck, CSL-Australia, CSL-New Zealand and Sanofi Pasteur MSD.
- Human papillomavirus